Navigation Links
FDA Approves PRE-PEN Penicillin Allergy Test

ALK-Abelló, Inc., and AllerQuest, LLC, are pleased to announce the return of PRE-PEN® penicillin allergy skin testing products to the market. PRE-PEN® received full FDA approval on September 18, 2009. ALK-Abelló has entered into a definitive agreement with AllerQuest to market and distribute PRE-PEN®.

Round Rock, TX (PRWEB) September 30, 2009 -- ALK-Abelló, Inc., and AllerQuest, LLC, are pleased to announce the return of PRE-PEN® to the market. Under the terms of the agreement, ALK will be the exclusive distributor of PRE-PEN®. PRE-PEN® received full FDA approval on September 18, 2009.

ALK-Abelló has entered into a definitive agreement with AllerQuest to market and distribute PRE-PEN® penicillin skin testing products. AllerQuest will manufacture the product in their FDA approved production facility in Plainville, Connecticut.

PRE-PEN® was a widely used skin test product for more than 30 years. In 2004, PRE-PEN® was withdrawn from the marketplace due to the lack of a dedicated penicillin manufacturing facility from the previous supplier. The loss of this product severely limited a physician's ability to test for penicillin sensitivity. In 2005, AllerQuest was formed to resurrect production of PRE-PEN® so that allergy specialists and hospitals could again have a skin test for penicillin sensitivity.

Jose A. Moreno Toscano, President of ALK-Abelló, Inc., stated, "ALK is excited to be the exclusive provider of PRE-PEN®. Our focus continues to be in providing allergy specialists with unique products such as PRE-PEN®, and value added services to assist with fighting the cause of allergy and driving more patients to the specialist for proper diagnosis and treatment of allergic disease."

Dr. Louis Mendelson, President of AllerQuest, LLC stated, "More than 30 million Americans are suspected to be allergic to penicillin, but extensive studies have demonstrated that most of these people may be able to be treated safely with penicillin and related antibiotics. In past years, in the absence of a penicillin test, allergy specialists were unable to test patients for penicillin sensitivity. AllerQuest has invested significant time and resources to bring this important product back into the US market, and we are pleased to bring this product to market with a company like ALK, which possesses strengths in marketing and world-wide distribution critical to the successful re-launching of PRE-PEN®."

Additional information can be found at

About ALK
ALK is a research driven global pharmaceutical company focusing on allergy treatment, prevention and diagnosis. ALK is the world leader in allergy vaccination (immunotherapy) - a treatment that induces a protective immune response which reduces and potentially halts the allergic reaction. Further information is available at

About AllerQuest, LLC
AllerQuest's mission is to develop skin test reagents to safely and accurately identify patients who are at risk for potentially life-threatening reactions to penicillin antibiotics. The company strives to ensure a reliable source of high quality test reagents to assist physicians in the diagnosis of penicillin allergy. Further information is available at


Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. FDA Approves Donor Screening Test for Antibodies to HIV
2. ClearWay Minnesota(SM) Board Approves New Officers
3. FDA Approves Vaccines for 2009 H1N1 Influenza Virus
4. FDA Approves 4 Swine Flu Vaccines
5. FDA Approves Valcyte(R) (valganciclovir hydrochloride) to Prevent Cytomegalovirus (CMV) Disease in Pediatric Patients Who Receive Heart or Kidney Transplants
6. FDA Approves XYZAL(R) For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria
7. Health Canada Approves Abbotts XIENCE V(R) Drug Eluting Stent
8. First 5 California Approves $81.4 Million Contribution to Help Restore Healthy Families Programs Viability
9. Video: FDA Approves EMBEDA(TM) For Management of Moderate to Severe Chronic Pain
10. FDA Approves New 3000 IU Vial Size for Kogenate(R) FS, antihemophilic factor (recombinant)
11. FDA Approves LIVALO(R) for Primary Hypercholesterolemia and Combined Dyslipidemia
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... ... software Q-Suite, announces the incorporation of Asterisk 11 LTS (Long Term Support) into ... Asterisk 11 LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that ...
(Date:11/26/2015)... ... , ... Inevitably when people think Thanksgiving, they also think Holiday sales and ... Friday and Cyber Monday massage chair sales to receive the best pricing ... to find the best massage chair deals, they can see all of the coupons ...
(Date:11/26/2015)... Ashburn, VA (PRWEB) , ... November 26, 2015 ... ... Planners, an American Express Travel Representative. As a franchise owner, Somu now offers ... range of cruise, destination wedding packages, private cruise sales, as well as, cabin ...
(Date:11/26/2015)... ... 26, 2015 , ... Jobs in hospital medical laboratories and in the imaging ... staffing agency Aureus Medical Group . These fields, as well as ... searching for healthcare jobs through the company’s website, , The leading ...
(Date:11/26/2015)... ... 26, 2015 , ... WorldCare International, Inc., the first company ... Employee Benefits Conference. The Employee Benefits Conference was hosted by the International Foundation ... 11th, 2015. The conference was held at the Hawaii Convention Center in Honolulu, ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 ... the addition of the "2016 Future Horizons ... Monitoring (TDM) Market: Supplier Shares, Country Segment Forecasts, ... offering. --> ... comprehensive analysis of the Japanese therapeutic drug monitoring ...
(Date:11/26/2015)... , November 26, 2015 ... of the "2016 Future Horizons and ... Abuse Testing Market: Supplier Shares, Country Segment ... to their offering. --> ... "2016 Future Horizons and Growth Strategies ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the European Therapeutic Drug Monitoring ... Forecasts, Competitive Intelligence, Emerging Opportunities"  report ... ) has announced the addition ...
Breaking Medicine Technology: